Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 28%
Hold 61%
Sell 0%
Strong Sell 0%

Bulls say

Humana is forecasted to achieve an increased earnings per share (EPS) of $17.06 for 2025, up from a previous estimate of $16.26, which reflects positive second-quarter results and revised guidance. The company's margin initiatives are expected to contribute to year-over-year earnings growth in 2027, despite the assumption that its Star ratings will remain stable without a recovery of bonus payments. Additionally, Humana's above-industry Medicare Advantage star rating positions the company favorably in a changing regulatory environment, enhancing its competitive standing in the health insurance market.

Bears say

The financial outlook for Humana is bleak, with management projecting a slight decline in earnings per share (EPS) for 2026 compared to 2025, primarily due to challenges associated with Star ratings, despite efforts to implement margin initiatives. There are significant downside risks that could further impact the company, including increased utilization in Medicare Advantage (MA), heightened competition, inadequate reimbursement rates, and a potential decline in membership for the Part D plan (PDP). Additionally, projections indicate that FY27 EPS could fall approximately 10% below estimates due to necessary investments aimed at recovering Star ratings, highlighting potential vulnerabilities in growth within its Healthcare Services segment.

Humana (HUM) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 28% recommend Buy, 61% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 18 analysts, Humana (HUM) has a Hold consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $294.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $294.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.